The transaction was approved by the Quebec Superior Court of Justice on Sept. 18 and by the U.S. Bankruptcy Court for the District of Delaware on Aug. 9. PWC said the liquidation of BioAmber’s assets will result in little to no residual value for non-secured creditors and no residual value for equity investors.